Clinical Trials Logo

Dry AMD clinical trials

View clinical trials related to Dry AMD.

Filter by:
  • None
  • Page 1

NCT ID: NCT03919019 Completed - Dry AMD Clinical Trials

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.

MACUPREV
Start date: January 18, 2018
Phase: N/A
Study type: Interventional

In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage. The Age-Related Eye Disease Study (AREDS) found that the intake of antioxidants reduces the risk of progression of the disease to an advanced stage (choroidal neovascularization or geographic atrophy ) and reduces the loss of visual acuity. In this study the investigators want to analyze the functional retinal changes (mfERG) of the macular region, in patients with dry age-related macular degeneration, after the use for 6 months of an oral supplementation based on Ganoderma lucidum (Reishi), Calendula Officinalis, Lutepure-Marigold ( 5% Lutein and 1% Zeaxanthin) Blueberry, Rutin, Alpha-lipoic acid, Bromelain, NAC, Vtiamine C, B9, B12, D3, Selenium, Zinc and Copper.

NCT ID: NCT03297515 Completed - Stargardt Disease 1 Clinical Trials

Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease

MADEOS
Start date: May 15, 2019
Phase: N/A
Study type: Interventional

Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS.

NCT ID: NCT00307398 Terminated - Dry AMD Clinical Trials

Anecortave Acetate Risk-Reduction Trial (AART)

Start date: March 2004
Phase: Phase 3
Study type: Interventional

A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.